目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.2.1 SECONDARY DATA
2.2.1.1 Key secondary sources
2.2.1.2 Key data from secondary sources
2.2.1.3 Objectives
2.2.2 PRIMARY DATA
2.2.2.1 Key primary sources
2.2.2.2 Key data from primary sources
2.2.2.3 Key industry insights
2.2.2.4 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Company revenue estimation approach
2.3.1.2 Presentations of companies and primary interviews
2.3.1.3 Growth forecast
2.3.1.4 CAGR projections
2.3.2 TOP-DOWN APPROACH
2.4 DATA TRIANGULATION
2.5 MARKET SHARE ANALYSIS
2.6 RESEARCH ASSUMPTIONS
2.6.1 PARAMETRIC ASSUMPTIONS
2.6.2 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS
4.1 POINT OF CARE DIAGNOSTICS MARKET OVERVIEW
4.2 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2024 VS. 2029
4.3 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2024 VS. 2029
4.4 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029
4.5 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2024 VS. 2029
4.6 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029
4.7 POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing incidence of infectious diseases
5.2.1.2 Increasing prevalence of chronic diseases
5.2.1.3 Favorable government initiatives for point of care testing
5.2.1.4 Rising number of waived tests
5.2.2 RESTRAINTS
5.2.2.1 Pricing pressure on manufacturers
5.2.2.2 Stringent regulatory approval process for product commercialization
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing growth potential in emerging markets
5.2.3.2 Rising inclination toward decentralized healthcare system
5.2.3.3 Booming healthcare spending worldwide
5.2.4 CHALLENGES
5.2.4.1 Inadequate standardization with centralized lab methods
5.2.4.2 Premium pricing of novel platforms
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER
5.4.3 AVERAGE SELLING PRICE, BY REGION
5.4.3.1 Average selling price of glucose monitoring test strips, by region
5.4.3.2 Average selling price of infectious disease testing products, by region
5.4.3.3 Average selling price of cardiometabolic monitoring products, by region
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Immunoassays
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Molecular diagnostics
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Biochemical technologies
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA FOR HS CODE 3822
5.11.2 EXPORT DATA FOR HS CODE 3822
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 PORTER'S FIVE FORCES ANALYSIS
5.13.1 BARGAINING POWER OF SUPPLIERS
5.13.2 BARGAINING POWER OF BUYERS
5.13.3 THREAT OF NEW ENTRANTS
5.13.4 THREAT OF SUBSTITUTES
5.13.5 INTENSITY OF COMPETITIVE RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.14.2 KEY BUYING CRITERIA
5.15 IMPACT OF AI ON POINT OF CARE DIAGNOSTICS MARKET
5.15.1 INTRODUCTION
5.15.2 MARKET POTENTIAL OF AI IN POINT OF CARE DIAGNOSTICS MARKET
5.15.3 AI USE CASES
5.15.4 KEY COMPANIES IMPLEMENTING AI
5.15.5 FUTURE OF AI IN POINT OF CARE DIAGNOSTICS MARKET
5.16 REGULATORY LANDSCAPE
5.16.1 REGULATORY ANALYSIS
5.16.1.1 North America
5.16.1.1.1 US
5.16.1.1.2 Canada
5.16.1.2 Europe
5.16.1.2.1 Germany
5.16.1.2.2 UK
5.16.1.2.3 France
5.16.1.2.4 Italy
5.16.1.2.5 Spain
5.16.1.3 Asia Pacific
5.16.1.3.1 China
5.16.1.3.2 Japan
5.16.1.3.3 India
5.16.1.3.4 Australia
5.16.1.3.5 South Korea
5.16.1.4 Latin America
5.16.1.4.1 Brazil
5.16.1.4.2 Mexico
5.16.1.5 Middle East
5.16.1.5.1 Africa
5.16.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.17 CASE STUDY ANALYSIS
5.17.1 CASE STUDY 1: IMPACT OF POINT OF CARE PCR TESTING FOR COMMUNITY-ACQUIRED PNEUMONIA IN DENMARK
5.17.2 CASE STUDY 2: ASSESSING POINT OF CARE VIRAL LOAD TESTING IMPACT ON HIV MONITORING IN NIGERIA
5.17.3 CASE STUDY 3: CLINICAL IMPACT OF ROUTINE MOLECULAR POINT OF CARE TEST FOR INFLUENZA IN HOSPITALIZED ADULTS

6 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
6.1 INTRODUCTION
6.2 GLUCOSE MONITORING PRODUCTS
6.2.1 GLUCOSE MONITORING STRIPS
6.2.1.1 Growing trend toward preventive healthcare to drive market
6.2.2 GLUCOSE MONITORING METERS
6.2.2.1 Growing technological advancements in glucose meters to propel market
6.2.3 GLUCOSE MONITORING LANCETS & LANCING DEVICES
6.2.3.1 Increasing tendency for home-based care and self-monitoring to aid growth
6.3 CARDIOMETABOLIC MONITORING PRODUCTS
6.3.1 CARDIAC MARKER TESTING PRODUCTS
6.3.1.1 Growing government support for cardiovascular diseases to drive market
6.3.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
6.3.2.1 Need to optimize hospital workflow to favor growth
6.3.3 HBA1C TESTING PRODUCTS
6.3.3.1 Increasing recommendations by government healthcare authorities to boost market
6.4 INFECTIOUS DISEASE TESTING PRODUCTS
6.4.1 RESPIRATORY INFECTION TESTING PRODUCTS
6.4.1.1 Influenza testing products
6.4.1.1.1 Need for targeted treatments to expedite growth
6.4.1.2 Tuberculosis
6.4.1.2.1 Increasing demand for diagnostic products and services to contribute to growth
6.4.1.3 Other respiratory infection testing products
6.4.2 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS
6.4.2.1 Growing rate of surgical-site infections to boost market
6.4.3 TROPICAL DISEASE TESTING PRODUCTS
6.4.3.1 Rising incidence of malaria and dengue to support growth
6.4.4 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS
6.4.4.1 HIV testing products
6.4.4.1.1 Growing availability and awareness of testing products to boost market
6.4.4.2 Hepatitis testing products
6.4.4.2.1 Hepatitis B testing products
6.4.4.2.1.1 Increasing prevalence of liver infections to favor growth
6.4.4.2.2 Hepatitis C testing products
6.4.4.2.2.1 Need to combat hepatitis among high-risk subgroup populations to aid growth
6.4.4.3 Syphilis testing products
6.4.4.3.1 Need for early and accessible diagnosis to expedite growth
6.4.4.4 Human papillomavirus testing products
6.4.4.4.1 Rising cases of cervical cancer to promote growth
6.4.4.5 Chlamydia trachomatis testing products
6.4.4.5.1 Growing adoption of advanced techniques to drive market
6.4.4.6 Neisseria gonorrhea testing products
6.4.4.6.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth
6.4.4.7 Herpes simplex virus testing products
6.4.4.7.1 Increasing incidence of herpes to support growth
6.4.5 CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS
6.4.5.1 Rising cases among hospitalized patients to boost demand
6.4.6 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
6.5 COAGULATION MONITORING PRODUCTS
6.5.1 PT/INR TESTING PRODUCTS
6.5.1.1 Increasing number of atrial fibrillation cases to accelerate growth
6.5.2 ACT/APTT TESTING PRODUCTS
6.5.2.1 Rise in surgical procedures to speed up growth
6.6 PREGNANCY & FERTILITY TESTING PRODUCTS
6.6.1 PREGNANCY TESTING PRODUCTS
6.6.1.1 Increasing awareness about family planning to stimulate growth
6.6.2 FERTILITY TESTING PRODUCTS
6.6.2.1 Growing infertility issues to fuel market
6.7 TUMOR/CANCER MARKER TESTING PRODUCTS
6.7.1 GROWING INVESTMENTS IN CANCER RESEARCH TO DRIVE MARKET
6.8 URINALYSIS TESTING PRODUCTS
6.8.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO AUGMENT GROWTH
6.9 CHOLESTEROL TESTING PRODUCTS
6.9.1 RISING OBESITY AND CARDIOVASCULAR DISEASES TO FOSTER GROWTH
6.10 HEMATOLOGY TESTING PRODUCTS
6.10.1 INCREASING CASES OF ANEMIA TO SUSTAIN GROWTH
6.11 DRUGS-OF-ABUSE TESTING PRODUCTS
6.11.1 GROWING CONSUMPTION OF ILLICIT DRUGS TO FAVOR MARKET
6.12 THYROID-STIMULATING HORMONE TESTING PRODUCTS
6.12.1 RISING PREVALENCE OF THYROID TO ENCOURAGE GROWTH
6.13 FECAL OCCULT TESTING PRODUCTS
6.13.1 GROWING INCIDENCE OF CANCER TO PROPEL MARKET
6.14 OTHER PRODUCTS

7 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE
7.1 INTRODUCTION
7.2 PRESCRIPTION-BASED TESTING PRODUCTS
7.2.1 RISING INCIDENCE OF CHRONIC DISEASES TO AUGMENT GROWTH
7.3 OTC TESTING PRODUCTS
7.3.1 GROWING PATIENT PREFERENCE FOR REMOTE HEALTHCARE TO PROPEL MARKET

8 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
8.1 INTRODUCTION
8.2 BIOCHEMISTRY
8.2.1 INCREASING PREVALENCE OF URINARY TRACT INFECTIONS TO EXPEDITE GROWTH
8.3 IMMUNOASSAYS
8.3.1 GROWING INCLINATION TOWARD DECENTRALIZED HEALTHCARE TO DRIVE MARKET
8.4 MOLECULAR DIAGNOSTICS
8.4.1 RT-PCR
8.4.1.1 Growing use of RT-PCR in proteomics and genomics to boost market
8.4.2 INAAT
8.4.2.1 Emerging new pathogens to facilitate growth

9 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE
9.1 INTRODUCTION
9.2 BLOOD SAMPLES
9.2.1 GROWING APPLICATION OF BLOOD SAMPLES IN DISEASE DETECTION TO DRIVE MARKET
9.3 NASAL & OROPHARYNGEAL SWABS
9.3.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO AID GROWTH
9.4 URINE SAMPLES
9.4.1 NEED FOR EARLY DETECTION AND MONITORING OF DIABETES-RELATED COMPLICATIONS TO PROPEL MARKET
9.5 OTHER SAMPLES

10 POINT OF CARE DIAGNOSTICS MARKET, BY END USER
10.1 INTRODUCTION
10.2 HOME CARE SETTINGS AND SELF-TESTING
10.2.1 INCREASING PREFERENCE AMONG WOMEN FOR CONFIDENTIALITY AND ACCESSIBILITY TO SUPPORT GROWTH
10.3 CLINICAL LABORATORIES
10.3.1 GROWING IMPROVEMENTS IN AUTOMATED TESTING SERVICES TO BOOST MARKET
10.4 HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS
10.4.1 RISING DEMAND FOR FAST DIAGNOSTIC SOLUTIONS TO SPUR GROWTH
10.5 AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES
10.5.1 NEED FOR RAPID RESULT GENERATION AND IMMEDIATE PATIENT CARE TO AID GROWTH
10.6 OTHER END USERS

11 POINT OF CARE DIAGNOSTICS MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Presence of advanced healthcare infrastructure and high healthcare expenditures to aid growth
11.2.3 CANADA
11.2.3.1 Rising incidence of diabetes and infectious diseases to support growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Increasing need for rapid and accurate diagnostic solutions to promote growth
11.3.3 FRANCE
11.3.3.1 Growing demand for accessible and convenient diagnostic tools to propel market
11.3.4 UK
11.3.4.1 Rising number of accredited clinical and hospital laboratories to sustain growth
11.3.5 ITALY
11.3.5.1 Growing burden of infectious and parasitic diseases to boost market
11.3.6 SPAIN
11.3.6.1 Rising prevalence of circulatory system diseases to contribute to growth
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Increasing impact of diabetes on public health to amplify growth
11.4.3 JAPAN
11.4.3.1 Booming geriatric population to stimulate growth
11.4.4 INDIA
11.4.4.1 Increasing cases of chronic heart and kidney diseases to foster growth
11.4.5 AUSTRALIA
11.4.5.1 Growing research investments for next-gen point of care devices to boost market
11.4.6 SOUTH KOREA
11.4.6.1 Growing focus on innovative diagnostic products to drive market
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Increasing public initiatives in healthcare to encourage growth
11.5.3 MEXICO
11.5.3.1 Need for frequent testing for disease management to expedite growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST & AFRICA
11.6.1 GROWING OUTBREAKS OF INFECTIOUS DISEASES AND EMPHASIS ON PREVENTIVE HEALTHCARE TO DRIVE MARKET
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
11.7 GCC COUNTRIES
11.7.1 BOOMING HEALTHCARE INFRASTRUCTURE TO FACILITATE GROWTH
11.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN POINT OF CARE DIAGNOSTICS MARKET
12.3 REVENUE ANALYSIS, 2021-2023
12.4 MARKET SHARE ANALYSIS, 2023
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/PRODUCT COMPARISON
12.6.1 ABBOTT
12.6.2 F. HOFFMANN-LA ROCHE LTD.
12.6.3 NOVA BIOMEDICAL
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
12.7.5.1 Company footprint
12.7.5.2 Region footprint
12.7.5.3 Mode of purchase footprint
12.7.5.4 Technology footprint
12.7.5.5 Sample footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
12.9.1 DETAILED LIST OF KEY STARTUPS/SMES
12.9.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
12.10 COMPETITIVE SCENARIO
12.10.1 PRODUCT LAUNCHES AND APPROVALS
12.10.2 DEALS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 ABBOTT
13.1.1.1 Business overview
13.1.1.2 Products offered
13.1.1.3 Recent developments
13.1.1.3.1 Product launches and approvals
13.1.1.3.2 Deals
13.1.1.4 MnM view
13.1.1.4.1 Right to win
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 SIEMENS HEALTHINEERS AG
13.1.2.1 Business overview
13.1.2.2 Products offered
13.1.2.3 Recent developments
13.1.2.3.1 Product launches and approvals
13.1.2.3.2 Deals
13.1.2.3.3 Expansions
13.1.2.4 MnM view
13.1.2.4.1 Right to win
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 F. HOFFMANN-LA ROCHE LTD
13.1.3.1 Business overview
13.1.3.2 Products offered
13.1.3.3 Recent developments
13.1.3.3.1 Product launches and approvals
13.1.3.3.2 Deals
13.1.3.3.3 Expansions
13.1.3.4 MnM view
13.1.3.4.1 Right to win
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 DANAHER
13.1.4.1 Business overview
13.1.4.2 Products offered
13.1.4.3 Recent developments
13.1.4.3.1 Deals
13.1.4.4 MnM view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 QUIDELORTHO CORPORATION
13.1.5.1 Business overview
13.1.5.2 Products offered
13.1.5.3 Recent developments
13.1.5.3.1 Product launches and approvals
13.1.5.3.2 Deals
13.1.5.3.3 Expansions
13.1.5.4 MnM view
13.1.5.4.1 Right to win
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses and competitive threats
13.1.6 BD
13.1.6.1 Business overview
13.1.6.2 Products offered
13.1.6.3 Recent developments
13.1.6.3.1 Deals
13.1.6.3.2 Expansions
13.1.7 THERMO FISHER SCIENTIFIC INC.
13.1.7.1 Business overview
13.1.7.2 Products offered
13.1.7.3 Recent developments
13.1.7.3.1 Product launches and approvals
13.1.7.3.2 Deals
13.1.8 BIOMERIEUX
13.1.8.1 Business overview
13.1.8.2 Products offered
13.1.8.3 Recent developments
13.1.8.3.1 Product launches and approvals
13.1.8.3.2 Deals
13.1.9 BIOSYNEX SA
13.1.9.1 Business overview
13.1.9.2 Products offered
13.1.9.3 Recent developments
13.1.9.3.1 Deals
13.1.10 EKF DIAGNOSTICS HOLDINGS PLC
13.1.10.1 Business overview
13.1.10.2 Products offered
13.1.10.3 Recent developments
13.1.10.3.1 Product launches and approvals
13.1.10.3.2 Deals
13.1.10.3.3 Expansions
13.1.11 TRINITY BIOTECH
13.1.11.1 Business overview
13.1.11.2 Products offered
13.1.11.3 Recent developments
13.1.11.3.1 Product launches and approvals
13.1.11.3.2 Deals
13.1.12 WERFEN
13.1.12.1 Business overview
13.1.12.2 Products offered
13.1.12.3 Recent developments
13.1.12.3.1 Product launches and approvals
13.1.12.3.2 Deals
13.1.13 NOVA BIOMEDICAL
13.1.13.1 Business overview
13.1.13.2 Products offered
13.1.13.3 Recent developments
13.1.13.3.1 Product launches and approvals
13.1.13.3.2 Expansions
13.1.14 SEKISUI DIAGNOSTICS
13.1.14.1 Business overview
13.1.14.2 Products offered
13.1.15 BODITECH MED INC.
13.1.15.1 Business overview
13.1.15.2 Products offered
13.1.15.3 Recent developments
13.1.15.3.1 Product launches and approvals
13.1.15.3.2 Deals
13.1.15.3.3 Expansions
13.2 OTHER PLAYERS
13.2.1 GRIFOLS, S.A.
13.2.2 LIFESCAN IP HOLDINGS, LLC
13.2.3 PTS DIAGNOSTICS
13.2.4 EUROLYSER DIAGNOSTICA GMBH
13.2.5 RESPONSE BIOMEDICAL
13.2.6 ALFA SCIENTIFIC DESIGNS, INC.
13.2.7 BTNX INC.
13.2.8 ASCENSIA DIABETES CARE HOLDINGS AG
13.2.9 FLUXERGY
13.2.10 PRECISION BIOSENSOR, INC.
13.2.11 ACON LABORATORIES, INC.
13.2.12 MENARINI DIAGNOSTICS S.R.L
13.2.13 ORASURE TECHNOLOGIES, INC.
13.2.14 MANKIND PHARMA

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS

List of Tables
TABLE 1 POINT OF CARE DIAGNOSTICS MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 POINT OF CARE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3 POINT OF CARE DIAGNOSTICS MARKET: RISK ASSESSMENT
TABLE 4 PROJECTED INCREASE OF CANCER PATIENTS, BY REGION, 2022 VS. 2035 VS. 2045
TABLE 5 GLOBAL DIABETES ESTIMATES (AGES 20-79) BY REGION, 2021 VS. 2030 VS. 2045 (IN THOUSANDS)
TABLE 6 PRODUCT WAIVERS, BY KEY PLAYER, 2021-2024
TABLE 7 AVERAGE SELLING PRICE OF POINT OF CARE TESTS, BY PRODUCT, 2022-2024
TABLE 8 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY KEY PLAYER, 2022-2024
TABLE 9 AVERAGE SELLING PRICE OF GLUCOSE MONITORING TEST STRIPS, BY REGION, 2022-2024
TABLE 10 AVERAGE SELLING PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022-2024
TABLE 11 AVERAGE SELLING PRICE OF CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022-2024
TABLE 12 POINT OF CARE DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 13 POINT OF CARE DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022-2023
TABLE 14 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 15 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 16 POINT OF CARE DIAGNOSTICS MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
TABLE 17 POINT OF CARE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
TABLE 19 KEY BUYING CRITERIA, BY TECHNOLOGY
TABLE 20 EUROPE: CLASSIFICATION OF IVD DEVICES
TABLE 21 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
TABLE 23 AUSTRALIA: CLASSIFICATION OF IVD MEDICAL DEVICES
TABLE 24 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 28 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 29 POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
TABLE 30 DIABETES-RELATED HEALTH EXPENDITURE PER PERSON, 2021 VS. 2030 VS. 2045 (USD)
TABLE 31 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 32 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 33 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 34 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 35 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 36 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 37 KEY GLUCOSE MONITORING STRIPS AVAILABLE WORLDWIDE
TABLE 38 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY REGION, 2022-2029 (USD MILLION)
TABLE 39 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 40 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 41 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 42 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING STRIPS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 KEY GLUCOSE MONITORING METERS AVAILABLE WORLDWIDE
TABLE 44 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 45 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 46 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 47 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 48 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING METERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 49 KEY GLUCOSE MONITORING LANCETS & LANCING DEVICES AVAILABLE WORLDWIDE
TABLE 50 POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY REGION, 2022-2029 (USD MILLION)
TABLE 51 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 52 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 53 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 54 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING LANCETS & LANCING DEVICES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 55 KEY CARDIOMETABOLIC MONITORING PRODUCTS AVAILABLE WORLDWIDE
TABLE 56 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 57 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 58 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 59 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 60 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 61 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 62 POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 63 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 64 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 65 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 66 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 67 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 68 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 69 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 70 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 71 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 72 POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 73 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 74 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 75 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 76 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 77 POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 78 POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 79 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 80 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 81 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 82 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 83 POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 84 POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 85 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 86 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 87 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 88 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 89 KEY INFLUENZA TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 90 POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 91 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 92 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 93 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 94 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 95 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 96 POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 97 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 98 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 99 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 100 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUBERCULOSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 101 OTHER KEY RESPIRATORY INFECTIONS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 102 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 103 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 104 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 105 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 106 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 107 KEY HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 108 POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 109 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 110 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 111 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 112 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 113 KEY TROPICAL DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 114 POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 115 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 116 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 117 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 118 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 119 POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 120 POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 121 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 122 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 123 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 124 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 125 KEY HIV TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 126 POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 127 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 128 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 129 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 130 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 131 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 132 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 133 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 134 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 135 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 136 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 137 KEY HEPATITIS B TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 138 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 139 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 140 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 141 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 142 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 143 KEY HEPATITIS C TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 144 POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 145 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 146 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 147 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 148 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 149 KEY SYPHILIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 150 POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 151 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 152 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 153 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 154 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR SYPHILIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 155 KEY HPV TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 156 POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 157 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 158 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 159 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 160 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HPV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 161 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 162 POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 163 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 164 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 165 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 166 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 167 POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 168 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 169 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 170 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 171 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHEA TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 172 KEY HSV TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 173 POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 174 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 175 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 176 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 177 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HSV TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 178 KEY CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 179 POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 180 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 181 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 182 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 183 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLOSTRIDIUM DIFFICILE INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 184 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 185 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 186 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 187 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 188 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 189 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 190 KEY COAGULATION MONITORING PRODUCTS AVAILABLE WORLDWIDE
TABLE 191 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 192 POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 193 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 194 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 195 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 196 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 197 POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 198 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 199 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 200 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 201 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 202 POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 203 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 204 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 205 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 206 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 207 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 208 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 209 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 210 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 211 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 212 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 213 KEY PREGNANCY TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 214 POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 215 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 216 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 217 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 218 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 219 KEY FERTILITY TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 220 POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 221 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 222 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 223 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 224 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 225 TYPES OF CANCER CASES WORLDWIDE, 2022 VS. 2045
TABLE 226 KEY TUMOR/CANCER MARKER TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 227 POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 228 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 229 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 230 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 231 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 232 KEY URINALYSIS TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 233 POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 234 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 235 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 236 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 237 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 238 KEY CHOLESTEROL TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 239 POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 240 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 241 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 242 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 243 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 244 KEY HEMATOLOGY TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 245 POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 246 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 247 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 248 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 249 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 250 KEY DRUGS-OF-ABUSE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 251 POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 252 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 253 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 254 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 255 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 256 POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 257 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 258 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 259 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 260 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR THYROID-STIMULATING HORMONE TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 261 KEY FECAL OCCULT BLOOD TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 262 POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 263 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 264 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 265 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 266 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 267 KEY OTHER POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 268 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 269 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 270 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 271 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 272 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 273 POINT OF CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
TABLE 274 KEY PRESCRIPTION-BASED TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 275 POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 276 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 277 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 278 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 279 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR PRESCRIPTION-BASED TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 280 KEY OTC TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 281 POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 282 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 283 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 284 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 285 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTC TESTING PRODUCTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 286 POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 287 KEY BIOCHEMISTRY-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 288 POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY REGION, 2022-2029 (USD MILLION)
TABLE 289 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 290 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 291 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 292 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 293 KEY IMMUNOASSAY-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 294 POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2022-2029 (USD MILLION)
TABLE 295 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 296 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 297 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 298 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 299 POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY TYPE, 2022-2029 (USD MILLION)
TABLE 300 POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 301 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 302 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 303 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 304 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 305 KEY RT-PCR-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 306 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY REGION, 2022-2029 (USD MILLION)
TABLE 307 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 308 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 309 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 310 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR RT-PCR, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 311 KEY INAAT-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 312 POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY REGION, 2022-2029 (USD MILLION)
TABLE 313 NORTH AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 314 EUROPE: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 315 ASIA PACIFIC: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 316 LATIN AMERICA: POINT OF CARE MOLECULAR DIAGNOSTICS MARKET FOR INAAT, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 317 POINT OF CARE DIAGNOSTICS MARKET, BY SAMPLE, 2022-2029 (USD MILLION)
TABLE 318 KEY BLOOD SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 319 POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022-2029 (USD MILLION)
TABLE 320 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 321 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 322 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 323 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 324 KEY NASAL AND OROPHARYNGEAL SWAB-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 325 POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY REGION, 2022-2029 (USD MILLION)
TABLE 326 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 327 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 328 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 329 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR NASAL & OROPHARYNGEAL SWABS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 330 KEY URINE SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 331 POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2022-2029 (USD MILLION)
TABLE 332 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 333 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 334 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 335 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 336 KEY OTHER SAMPLE-BASED POINT OF CARE TESTING PRODUCTS AVAILABLE WORLDWIDE
TABLE 337 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY REGION, 2022-2029 (USD MILLION)
TABLE 338 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 339 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 340 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 341 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 342 POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 343 POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY REGION, 2022-2029 (USD MILLION)
TABLE 344 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 345 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 346 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 347 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS AND SELF-TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 348 POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 349 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 350 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 351 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 352 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 353 POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 354 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 355 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 356 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 357 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS, CRITICAL CARE CENTERS, AND URGENT CARE CENTERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 358 POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY REGION, 2022-2029 (USD MILLION)
TABLE 359 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 360 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 361 ASIA PACIFIC: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 362 LATIN AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES AND PHYSICIAN OFFICES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 363 POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 364 NORTH AMERICA: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 365 EUROPE: POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 366 ASIA PACIFIC: PO